51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial
Recommended Citation
Lebwohl M, Bukhalo M, Stein-Gold L, Pelle M, Glick B, Llamas-Velasco M, Sanchez-Rivera S, Zhan T, Drogaris L, Espaillat R, Bissonnette R. 51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial. J Am Acad Dermatol 2024; 91(3):AB306.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Introduction: Risankizumab (RZB) is an IL-23 inhibitor approved for the treatment of moderate-to-severe psoriasis (PsO). Here, we assess improvement in dermatology life quality index (DLQI) in patients with non-pustular palmoplantar psoriasis (PPPsO) PPPsO receiving risankizumab (RZB). Methods: IMMprint (NCT04713592) is a phase 3b double-blind, placebo-controlled study evaluating the safety and efficacy of RZB in patients with predominately PPPsO. Eligible patients (≥18 years) were randomized 1:1 to receive RZB 150mg (week 0, 4 and 16) or placebo (PBO). At week 16, all patients received open-label RZB 150mg every 12 weeks (PBO/RZB vs. RZB/RZB) till week 40 with a final evaluation at week 52. DLQI was assessed by Mixed-effect Model Repeat Measure analysis to handle missing data in period A and Observed Cases in period B. Safety was monitored throughout the study. Results: The change from baseline in DLQI (RZB vs. PBO, nominal p-value) was -4.5 vs. -0.5, p < 0.001) at week 16 and -8.2 vs. -8.3 (PBO/RZB vs. RZB/RZB) at week 52. The proportion of patients achieving DLQI 0/1 was 25.3% vs. 4.6%, p < 0.001 at week 16 and 35.6% vs. 46.9% (PBO/RZB vs. RZB/RZB) at week 52. The proportion of patients who achieved DLQI reduction ≥4 among baseline DLQI ≥ 4 was 58.6% vs 33.3%, p < 0.001 at week 16 and 65.7% vs. 76.2% (PBO/RZB vs. RZB/RZB) at week 52. No new safety signals were indicated. Conclusions: Systemic-eligible patients with moderate-to-severe PPPsO treated with RZB demonstrated improved quality of life assessed by DLQI.
Volume
91
Issue
3
First Page
AB306
